Clinical trials: Ductal Carcinoma
Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal or intrahepatic CCA with indication for bile duct…
- Trial name
- NCT06440993
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- 12 sites in Germany
- Volunteers
- 42 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Mammary Tumor, Nipple Discharge
A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts
This prospective, multicenter cohort study investigates the differences in the reliability of rapid pathology compared to postoperative pathology when utilizing a novel fluorescent localization needle equipped with a controllable…
- Conditions
- Mammary Tumor, Nipple Discharge, Breast Ductal Carcinoma In Situ
- Trial name
- NCT07339306
- Testing
- novel fluorescent localization marker needle, conventional localization marker needle
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Fourth Affiliated Hospital of China Medical University
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00295893
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- City of Hope Medical Center
DCIS
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
- Trial name
- ELISA (NCT04797299)
- Where
- 24 sites in Canada
- Volunteers
- 526 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer, Ductal Carcinoma in Situ
Breast MRI as a Preoperative Tool for DCIS
Breast MRI is a fairly new technology, but it has been well studied. It is now used routinely in many patients with breast cancer.
- Trial name
- NCT00605982
- Testing
- MRI
- Where
- 3 sites in United States
- Volunteers
- 115 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ductal Carcinoma In Situ, DCIS
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery
This is a single-center, prospective phase II clinical study designed to evaluate whether omission of postoperative radiotherapy is clinically acceptable in young patients with low-risk ductal carcinoma in situ (DCIS) following…
- Trial name
- NCT07762924
- Testing
- Observation, Endocrine Therapy (Optional)
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Fudan University
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
This randomized pilot clinical trial studied whether the Oncotype DX gene expression "Recurrence Score" (RS) would be useful for helping make a decision about which type of pre-operative treatment, hormone therapy or chemotherapy…
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT01293032
- Testing
- Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Virginia Commonwealth University
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia
Molecular Breast Imaging in Women With Atypia and LCIS
We aim to determine if Molecular Breast Imaging (a new nuclear medicine technique developed at Mayo) can identify malignant breast lesions in women who have atypical ductal hyperplasia, atypical lobular hyperplasia, or lobular…
- Conditions
- Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
- Trial name
- NCT00620087
- Testing
- Molecular Breast Imaging, Screening Mammography
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
IACS-010759 in Advanced Cancers
This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 (IACS-010759) in treating patients with lymphoma that has come back (relapsed) or does not respond to treatment…
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT03291938
- Testing
- Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Medullary Thyroid Cancer
Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients
The purpose of this study is to determine which Health Related Quality of Life (HRQoL) tools patients with medullary thyroid cancer (MTC) find most helpful.
- Trial name
- QaLM (NCT02465424)
- Testing
- quality of life questionnaires
- Where
- 7 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- Velindre NHS Trust
Non-small Cell Lung Cancer, Colorectal Cancer
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04121286
- Testing
- JAB-3312
- Where
- 5 sites in China
- Volunteers
- 17 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Invasive Ductal Carcinoma, Invasive Lobular Carcinoma
Intraoperative Imaging of Breast Cancer With Indocyanine Green
According to the World Health Organization, breast cancer is the most common cancer in women, and is responsible for 686,000 new cases every year. The WHO also posit that nearly 420,000 women perished from the disease in 2002.
- Conditions
- Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Ductal Carcinoma
- Trial name
- ICG (NCT01796041)
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Medullary Thyroid Cancer
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC.
- Trial name
- EXAMINER (NCT01896479)
- Testing
- Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg
- Where
- 49 sites in Australia, Canada and 12 more
- Volunteers
- 247 people
- Sponsor
- Exelixis
Pancreatic Ductal Adenocarcinoma (mPDAC), Metastatic Colorectal Carcinoma (mCRC)
OSCAR II STUDY - The ONCObind CTC Removal Study
This study is a Prospective Single Arm, dual cohort Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in either mPDAC or mCRC…
- Trial name
- NCT06655142
- Testing
- ONCObind (Onco-Seraph) 100 Filter, Matched Controls
- Volunteers
- 120 people
- Sponsor
- ExThera Medical Corporation
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Colorectal Carcinoma, Gastric Carcinoma
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread.
- Conditions
- Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06882746
- Testing
- BI 765049
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, DCIS
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by…
- Conditions
- Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
- Trial name
- NCT05900986
- Testing
- LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Integro Theranostics
Infiltrating Ductal Carcinoma
Contribution of 18FDG PET-Scan in Tumour Volume Determination in Patients Operated of Breast Cancer
Use of positron emission tomography (PET) in determination of functional tumour volume can provide usable information for radiotherapy to define the irradiated volume.
- Trial name
- VOSETEP (NCT01621529)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Henri Becquerel
Medullary Thyroid Cancer
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC…
- Trial name
- AcceleRET-MTC (NCT04760288)
- Testing
- Pralsetinib, Cabozantinib, Vandetanib
- Where
- Spain
- Sponsor
- Hoffmann-La Roche